**Name of Journal: *World Journal of Clinical Cases***

**Manuscript NO: 50466**

**Manuscript Type: ORIGINAL ARTICLE**

***Retrospective Study***

**Rh-incompatible hemolytic disease of the newborn in Hefei**

Bi SH *et al*. Rh-HDN in Chinese

**Shao-Hua Bi, Liang-Liang Jiang, Li-Ying Dai, Hong Zheng, Jian Zhang, Li-Li Wang, Chao Wang, Qiao Jiang, Yu Liu, Yong-Li Zhang, Juan Wang, Chao Zhu, Guang-Hui Liu, Ru-Jeng Teng**

**Shao-Hua Bi,** **Li-Ying Dai, Hong Zheng,** **Jian Zhang, Yu Liu, Yong-Li Zhang,** **Juan Wang, Guang-Hui Liu,** Divisions of Neonatology, Anhui Provincial Children’s Hospital, Hefei 230022, Anhui Province, China

**Liang-Liang Jiang,** Pediatrics Neurology, Anhui Provincial Children’s Hospital, Hefei 230022, Anhui Province, China

**Li-Li Wang,** **Chao Zhu,** Division of Neonatology, First Affiliated Hospital of Anhui Medical University, Hefei 230022, Anhui Province, China

**Chao Wang,** Hefei Blood Center, Hefei 230022, Anhui Province, China

**Qiao Jiang,** Clinical Pathology, Anhui Provincial Children’s Hospital, Hefei 230022, Anhui Province, China

**Ru-Jeng Teng,** Division of Neonatology, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI 53226, United States

**ORCID number:** Shao-Hua Bi (0000-0001-5844-3072); Liang-Liang Jiang (0000-0001-7624-0439); Li-Ying Dai (0000-0003-3914-9155); Hong Zheng (0000-0002-5437-4193); Jian Zhang (0000-0001-5218-003X); Li-Li Wang (0000-0002-1134-0559); Chao Wang (0000-0002-5492-5127); Qiao Jiang (0000-0001-6568-0471); Yu Liu (0000-0002-4573-9090); Yong-Li Zhang (0000-0001-7878-7630); Juan Wang (0000-0001-7184-9085); Chao Zhu (0000-0002-6467-2071); Guang- Hui Liu (0000-0002-1682-6187); Ru-Jeng Teng (0000-0003-4321-2452).

**Author contributions:** Bi SH and Teng RJ designed the research; Bi SH, Liu GH, and Teng RJ drafted the manuscript; Bi SH, Jiang LL, Dai LY, Zheng H, Zhang J, Liu Y, Zhang YL, and Wang J obtained informed consent and reviewed the medical records; Wang C and Jiang Q performed the laboratory tests; Bi SH, Zhu C, Liu GH, and Teng RJ performed the data analysis; Wang LL, Zhu C, Liu GH, and Teng FJ revised the manuscript; Bi SH, Zhu C, Liu GH, and Teng RJ finalized the manuscript.

**Institutional review board statement:** See uploaded file for IRB approval in Chinese.

**Conflict-of-interest statement:** The authors report no relevant conflicts of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Data sharing statement:** Deidentified raw data can be obtained from the authors upon official request for research purpose only.

**Corresponding author:** **Guang-Hui Liu, MD, Chief Doctor,** Division of Neonatology, Anhui Provincial Children’s Hospital, Anhui Medical University, Wangjiang E. Rd, Hefei 230022, Anhui Province, China. lgh508@sina.com

**Telephone:** +86-551-62237807

**Received:** July 23, 2019

**Peer-review started:** July 23, 2019

**First decision:** September 9, 2019

**Revised:** September 22, 2019

**Accepted:** October 5, 2019

**Article in press:**

**Published online:**

**Abstract**

***Background***

Anti-D antibody is not the common cause of Rh-isoimmunization in Chinese neonatal jaundice. A recent change in the national population policy has been followed by an increase in Rh-isoimmunization related hemolytic disease of the newborn (HDN). Unfortunately, regional status of Rh-HDN is unavailable. We hypothesize that Rh-HDN in our region is most commonly due to anti-E antibody.

***AIm***

To investigate the prevalence of hemolytic disease of the newborn due to Rh-isoimmunization in Hefei City.

***Methods***

Retrospective review of data obtained from Children’s Hospital of Anhui and Hefei Blood Center between January 2017 and June 2019. Status of minor blood group antibody was studied in the corresponding mothers.

***Results***

In total, 4138 newborns with HDN were admitted during the study period and 116 (2.8%) received blood exchange transfusion (BET). Eighteen newborns (0.43%) with proven Rh-incompatible HDN were identified. All were not the first-born baby. Thirteen mothers were RhD (+) (72%) and five were RhD (-). The distribution of Rh-related antibodies in mothers was 10 anti-E (55%), 5 anti-D (27%), and 1 each for anti-C, anti-c, and anti-E/c (6%). Thirteen (72.2%) qualified for BET, relative risk for BET was 28.9 as compared to other types of HDN, but only 10 received BET due to parenteral refusal. All (100%) RhD related HDN received BET, which was not significantly different from RhE related HDN (81.8%).

***Conclusion***

As expected, all Rh-incompatible HDN newborns were not the first-born. Contrary to the Caucasian population, anti-D induced HDN is not the most common etiology in Chinese neonates. In our region, anti-E (11/18, 61%) is the most common cause of Rh-HDN.

**Key words:** Rh-isoimmunization; Hemolytic disease of the newborn; Minor blood group

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Rh-hemolytic disease of the newborn (HDN) is more common in China after the change in the national population policy. In contrast to Caucasians, the most common antibody that causes Rh-HDN in Chinese neonates is the anti-E antibody. The severity of anti-E Rh-HDN seems no less than that of anti-D Rh-HDN since most of our indexed cases qualified for blood exchange transfusion. This emerging medical problem requires a nationwide collaboration of research in order to establish evidence-based guidelines for the Chinese population.

Bi SH, Jiang LL, Dai LY, Zheng H, Zhang J, Wang LL, Wang C, Jiang Q, Liu Y, Zhang YL, Wang J, Zhu C, Liu GH, Teng RJ.Rh-incompatible hemolytic disease of the newborn in Hefei. *World J Clin Cases* 2019; In press

**Introduction**

Hemolytic disease of the newborn (HDN), or erythroblastosis fetalis, is due to blood type incompatibility between the mother and the fetus. This incompatibility causes the mother’s immune system to generate immunoglobulin G (IgG) antibody against the blood type of the fetus. The IgG antibody binds to fetal red blood cells transplacentally to cause hemolysis. ABO isoimmunization is the most common etiology for HDN, but minor blood group isoimmunization can also cause severe HDN. Different from ABO-HDN, minor blood group HDN usually will not occur in the first-born newborn unless the mother has prior abortion, inadequate transfusion, or miscarriage. During the era of one-child policy, we had extremely limited experience with minor blood group HDN. There were only a few reports about minor blood group HDN in China[1-3]. After discontinuation of the one-child policy, we believe that pediatricians will start to experience more minor blood group HDN.

Our clinical experience tells us that Rh-isoimmunization is the second most common cause of HDN in Chinese newborns[1,3]. Without early recognition, Rh-HDN can cause severe neonatal jaundice that can complicate with kernicterus or death. Severe Rh-HDN can also lead to fetal demise, miscarriage, or premature birth. Neutropenia and thrombocytopenia can be a clinical manifestation of newborns with Rh-HDN[4,5]. Occasionally, the fetal hydropic change can cause uterine atony, maternal preeclampsia, mirror (Ballantyne) syndrome[6], or difficulty in cross-matching. Early identification of the at-risk pregnancy and intrauterine intervention may offer a better outcome of the newborn and the mother. After the introduction of Rhogam in the 1960s, problems from Rh-isoimmunization were almost eradicated[7]. However, we do not know whether Rhogam can offer similar benefit to our population or not. Currently, our medical society still lacks adequate data to guide us to develop a rational management pathway. Our study is aimed to bring attention to Rh-HDN in Chinese population.

**MATERIALS AND METHODS**

We prospectively initiated a collaboration between Anhui Provincial Children’s Hospital and Hefei Blood Center for this cohort study. Blood types of parents and the newborns, hemolysis, and antibodies of minor blood groups were tested for all newborns admitted for neonatal jaundice. Both coagulated and anti-coagulated blood from mother and newborn was collected according to the Chinese National Standardized Protocols for Clinical Laboratory, 4th version, for saline cross matching, polybrene test, and Coombs test. Antibodies against Rh group including anti-D, anti-E, anti-e, anti-C, and anti-c were tested together with ant-A and anti-B. Blood was also tested for hemoglobin, non-specific antibody, reticulocyte count, direct Coombs test, and indirect Coombs test. The study started from January 2017 and was completed June 2019. Consent for data collection was obtained from the parents. Due to limited case numbers, non-parametric test was used for comparisons between two groups. Fisher’s exact test was used to compare categorical data between two groups. Data were analyzed by Prism 8 (La Jolla, CA, United States) for Windows v.8.1.2.

**Results**

Our hospital adopted the American Academy of Pediatrics guidelines published in 2004 to diagnose and manage neonatal jaundice[8]. During the study period there were in total 4138newborns admitted for neonatal hyperbilirubinemia, and 116 (2.8%) of them received double-volume blood exchange transfusion (BET). There were 18 mother-newborn dyads in our study (0.4%) without ABO incompatibility. Among those 18 mothers, 3 were blood type A, 6 were blood type B, 5 were blood type O, and 4 were blood type AB. Thirteen mothers were RhD (+), and five were RhD (-) (Table 1). Direct Coombs test, free antibody test, and antibody release test were positive for all 18 index cases. Thirteen out of the 18 newborns (55.6%) were qualified for BET, but 3 of them did not undergo the procedure due to refusal by their parents. This left only 10 newborns who received BET, which accounted for 8.6% of all newborns who received BET during the study period. Rh-HDN had much higher risk to be qualified for BET (relative risk = 28.9, odds ratio = 101.4; *p* < 0.0001 by Fisher exact test). All three newborns qualified for BET but did not receive the procedure were born to RhD (+) mothers with anti-E antibody. Among the 10 newborns received BET, five newborns were from RhD (-) mothers and five were from RhD (+) mothers. There was no difference in the percentage requiring BET between newborns from RhD (-) mothers and RhD (+) mothers (5/5 *vs* 8/13, *p* = 0.25 by Fisher exact test). All 10 newborns tolerated the exchange transfusion and were discharged home without complication. Fifteen newborns (83.3%) were the second born while three (16.7%) were the third born. The reticulocyte counts ranged between 1.12% and 25.3%. Though the median reticulocyte count was higher for newborns from RhD (-) mothers (18.53% *vs* 8.37%), the difference was not statistically significant (*p* = 0.40). There were 10 mothers with E antibody (55%), 5 with anti-D antibody (27%), 1 with both anti-E and anti-c antibodies (6%), and 1 each for anti-C (6%) and anti-c antibodies (6%).

**Discussion**

Blood group isoimmunization has been known to be a major cause of hydrops fetalis since 1940s[9] and the most important cause of neonatal jaundice[8]. The most common etiology of blood group isoimmunization is ABO-isoimmunization, while Rh-isoimmunization is the second most common etiology. However, before the introduction of Rhogam, Rh-isoimmunization used to be the most common cause of kernicterus[9]. After exposure to fetal blood with different blood type, the maternal immune system can be sensitized to generate IgG antibody, an isotype that can cross placenta into fetal circulation to hemolyze fetal red blood cells[10]. The introduction of postpartum Rhogam injection has successfully reduced the Rh (D) sensitization from 14% to 1%-2%, and the addition of antepartum Rhogam injection further reduced the sensitization down to 0.5%[11]. Unfortunately, this successful experience cannot be applied to our population since less than 1% of pregnant women is RhD (-).

Although Rh-HDN only accounted for less than 1% (0.43%) of all HDN admission in our hospital, the relative risk for requiring BET was 28.9-fold the other type of HDN. With roughly 7 cases per year (18 cases over 2.5 years) in our hospital, Rh-HDN is not an uncommon problem we are facing. Rh blood group system is one of more than 40 known human blood group systems. There are two sets of nomenclatures for Rh blood group, one developed by Fisher *et al*[12] and the other by Wiener[13]. The Fisher system is more commonly used by clinicians and contains three classes of epitope (C, c, D, d, E, e) and are encoded by two adjacent gene loci on chromosome 1. Due to their proximity on the DNA, the three classes of epitope co-express in a complex pattern with at least 34 genotypes. The potency of antigenicity studied show D > E > C > c > e > d, which explains the severity of neonatal jaundice caused by the corresponding antibody.

As compare to ABO-HDN, the Rh-HDN has more aggressive hemolysis as reflected by more of the patients requiring BET. It is believed that fetal red blood cells express less A/B antigen on the cell membrane, and A/B antigen is also expressed on other cell types that can decrease the binding of antibody to the red blood cells.

The D gene (D or d) is located on the short arm (p) of chromosome 1, with 94% population as RhD (+) and 6% RhD (-) globally. Caucasian has the highest (15%) RhD (-) compared to Black (8%) and Asian population (< 1%)[14], which makes the Rh (D) isoimmunization extremely rare in Chinese population. C (C or c) and E (E or e) are co-expressed due to their proximity. The genotype distribution of C (68%Caucasian, 27%Black, and 93%Asian), c (80%Caucasian, 96%Black, and 47%Asian), E (29%Caucasian, 22%Black, and 39%Asian), and e (98%Caucasian, 98%Black, and 96%Asian)[15] is in agreement with previous reports, suggesting isoimmunization against E and c is more common in the Chinese population[1,3]. In our results, only five HDN were associated with anti-D antibody. However, all five HDN with anti-D antibody received BET as compared to eight out of 13 (61.5%) in anti-D negative newborns who qualified for BET, although three did not receive it due to parenteral refusal.

Since Rh-HDN is very rare in Chinese population and rarely occurs in the first pregnancy, unless there was a prior abortion or miscarriage, our medical community really lacks knowledge of this morbidity, especially during the one-child policy era. Rh (D) mediated HDN is just one kind of Rh-HDN that can be prevented or managed by Rhogam. Unfortunately, there is no role for Rhogam in C, c, E, or e antibody mediated HDN. With the recent reversion of the one-child policy, we can expect the number of CcEe-mediated HDN may increase, and we need to prepare for this change. We pediatricians need to be aware that Rh (+), as we commonly call those RhD (+) pregnant women, does not guarantee that there is no risk for the development of Rh-HDN in newborns. We also need to know that first-born newborn is not completely protected from Rh-HDN if the mother had prior abortion, transfusion, or miscarriage. Our obstetric colleagues are recommended to provide at least 500 international units (I.U.) Rhogam injection to pregnant women at 28 wk and 34 wk gestation or one 1500 I.U. injection at 28 wk gestation to RhD (-) pregnant women, followed by a 500 I.U. injection within 72 h after delivery to prevent Rh (D) sensitization if they are Rh (D)-negative with a Rh (D)-positive sex partner.

In the presence of ABO incompatibility, the chance to develop Rh sensitization decreases dramatically by at least 2.4-fold[16]. This protective effect is believed to come from the higher antigenicity of the ABO blood group. It is interesting that none of our newborns complicated with ABO incompatibility, but clinical significance deserves more extensive multi-institutional studies in the future. During clinical work-up, it is important to note that direct Coombs test can be negative in severe Rh-HDN due to extremely high titer of the antibody[17]. Contrary to Rhogam, Anti-E antibody is presently not available for preventing and treating anti-E mediated HDN. However, non-specific intravenous immunoglobulin can be used to ameliorate the severity of hemolysis and hence the jaundice[18].

In conclusion, Rh-HDN is an infrequent cause of HDN but can elicit severe hemolysis. In the present era, we need to be more familiar with the spectrum of this disease since most of our Rh-HDN is not due to anti-D antibody and cannot be prevented by the Rhogam injection. Our results only represent our regional experience. An extensive collaboration between pediatrician, obstetricians, and transfusion experts is required for a better understanding of Rh-HDN that can help us to establish a proper guideline in management.

**Article Highlights**

***Research background***

Before the discontinuation of the national population one-child policy, Rh-hemolytic disease of the newborn (HDN) was a rare cause of severe neonatal jaundice in China. Different from Caucasian population, RhD (-) is extremely rare in Chinese. We have experienced a dramatic increase in Rh-HDN since the discontinuation of the national population policy that we believe will impact our management of neonatal jaundice nationwide. The lack of our own epidemiologic data will hinder our generation of a public health policy judging from the severe consequence of bilirubin induced neurologic deficit.

***Research motivation***

To share our experience with our colleagues to encourage a statewide or nationwide collaboration to study Rh-HDN in Chinese.

***Research objectives***

To investigate the distribution of Rh antibodies in Chinese HDN and its clinical manifestations.

***Research methods***

Retrospective chart review of prospectively collected cohort over 18 mo in one free standing Children’s Hospital.

***Research results***

Rh-HDN accounted for 0.43% (18 out of 4138) of all HDN, and 72.2% (13/18) were qualified for blood exchange transfusion. No mother received antenatal Rhogam injection. The most common antibody involved was anti-E (55%, 10/18). The risk for blood exchange transfusion was similar between anti-D (100%) and anti-E (81.8%) Rh-HDN.

***Research conclusions***

Anti-E antibody is the most common cause of Rh-HDN in Chinese. Our limited experience showed the severity of RhE neonatal jaundice is no less severe than RhD neonatal jaundice.

***Research perspectives***

More extensive study in Rh-HDN is warranted following the change of our national population policy. The severity of Rh-HDN to both pregnant women and fetus deserve our attention. Collaboration among perinatology, neonatology, hematology, and immunology is needed to provide the best care for our next generation.

**AcknowledgementS**

Thanks forall the nursing staff, medical technicians, and medical informatics of the Anhui Provincial Children’s Hospital and Hefei Blood Center. Without their help this study could not be accomplished.

**References**

1 **Lee SK**, Tham KT, Cheung KP, Jenkins WJ. Rh(D) fraction incompatibility causing hemolytic disease of the newborn. Report of two cases in a Chinese family. *Am J Clin Pathol* 1982; **78**: 95-96 [PMID: 6808826 DOI: 10.1093/ajcp/78.1.95]

2 **Lin SW**, Lin DT, Hsieh SW, Hsieh PK, Teng RJ, Tsou KI, Lin KS. Hemolytic disease of the newborn caused by anti-M antibody. *J Formos Med Assoc* 1996; **95**: 390-392 [PMID: 8688704]

3 **Wu KH**, Chu SL, Chang JG, Shih MC, Peng CT. Haemolytic disease of the newborn due to maternal irregular antibodies in the Chinese population in Taiwan. *Transfus Med* 2003; **13**: 311-314 [PMID: 14617342]

4 **Koenig JM**, Christensen RD. Neutropenia and thrombocytopenia in infants with Rh hemolytic disease. *J Pediatr* 1989; **114**: 625-631 [PMID: 2494315 DOI: 10.1016/s0022-3476(89)80709-7]

5 **Lalezari P**, Nussbaum M, Gelman S, Spaet TH. Neonatal neutropenia due to maternal isoimmunization. *Blood* 1960; **15**: 236-243 [PMID: 14413526]

6 **Singh Y**, Kathpalia SK, Singh S. Ballantyne Syndrome in Rhesus Isoimmunised Pregnancy. *Med J Armed Forces India* 2010; **66**: 283-284 [PMID: 27408320 DOI: 10.1016/S0377-1237(10)80064-4]

7 **Pollack W**, Gorman JG, Freda VJ, Ascari WQ, Allen AE, Baker WJ. Results of clinical trials of RhoGAM in women. *Transfusion* 1968; **8**: 151-153 [PMID: 4173363 DOI: 10.1111/j.1537-2995.1968.tb04895.x]

8 **American Academy of Pediatrics Subcommittee on Hyperbilirubinemia**. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. *Pediatrics* 2004; **114**: 297-316 [PMID: 15231951 DOI: 10.1542/peds.114.1.297]

9 **Levine P,** Burnham L, Katzin EM, Vogel P. The role of iso-immunization in the pathogenesis of erythroblastosis fetalis. *Am J Obstet Gynecol* 1941; **42**:925-937 [DOI: 10.1016/S0002-9378(41)90260-0]

10 **Bhutani VK**, Zipursky A, Blencowe H, Khanna R, Sgro M, Ebbesen F, Bell J, Mori R, Slusher TM, Fahmy N, Paul VK, Du L, Okolo AA, de Almeida MF, Olusanya BO, Kumar P, Cousens S, Lawn JE. Neonatal hyperbilirubinemia and Rhesus disease of the newborn: incidence and impairment estimates for 2010 at regional and global levels. *Pediatr Res* 2013; **74 Suppl 1**: 86-100 [PMID: 24366465 DOI: 10.1038/pr.2013.208]

11 **Basu S**, Kaur R, Kaur G. Hemolytic disease of the fetus and newborn: Current trends and perspectives. *Asian J Transfus Sci* 2011; **5**: 3-7 [PMID: 21572705 DOI: 10.4103/0973-6247.75963]

12 **Fisher RA,** Race RR, Taylor GL. Mutation and the Rhesus reaction. Nature 1944; **153**: 106.

13 **Wiener AS**. The Rh-Hr blood types: serology, genetics, and nomenclature. *Trans N Y Acad Sci* 1951; **13**:199-204 [PMID:14855598]

14 **Golassa L**, Tsegaye A, Erko B, Mamo H. High rhesus (Rh(D)) negative frequency and ethnic-group based ABO blood group distribution in Ethiopia. *BMC Res Notes* 2017; **10**: 330 [PMID: 28747227 DOI: 10.1186/s13104-017-2644-3]

15 **Castillo B,** Dasgupta A, Klein K, Tint H, Wahed A. Transfusion Medicine for Pathologists: A Comprehensive Review for Board Preparation, Certification, and Clinical Practice. Elsevier (1st Edition), 2018, 69-112.

16 **Donohue WL**, Wake EJ. Effect of Abo Incompatibility on Pregnancy-Induced Rh Isoimmunization. *Can Med Assoc J* 1964; **90**: 1-5 [PMID: 14105011]

17 **Murray NA**, Roberts IA. Haemolytic disease of the newborn. *Arch Dis Child Fetal Neonatal Ed* 2007; **92**: F83-F88 [PMID: 17337672 DOI: 10.1136/adc.2005.076794]

18 **Singh Y**, Kathpalia SK, Singh S. Ballantyne Syndrome in Rhesus Isoimmunised Pregnancy. *Med J Armed Forces India* 2010; **66**: 283-284 [PMID: 27408320 DOI: 10.1016/S0377-1237(10)80064-4]

**P-Reviewer:** Aydin M,Govindarajan GK **S-Editor:** Zhang L

**L-Editor:** Filipodia **E-Editor:**

**Specialty type:** Medicine, Research and Experimental

**Country of origin:** China

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

**Table 1 Blood group information of the parents and newborn, maternal pregnancy status, and laboratory data of the newborns**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Case** | **Blood type, F** | **Blood type, M** | **Blood type, N** | **Direct Coombs** | **Free antibody test** | **Antibody release test** | **Minor blood group** | **BET** | **RhD** | **Gestation** | **Reticulocyte count, %** | **Gestational age, wk** | **Age** | **T-bil, µmol/L** | **D-bil, µmol/L** | **Hb,** |
| **test** | **g/L** |
| 1 | O | O | O | + | + | + | E | Y | - | G3P3 | 4.10 | 41+0 | 5d | 406.1 | 100.8 | 133 |
| 2 | O | B | B | + | + | + | E | N1 | + | G4P2 | 4.50 | 39+5 | 33h | 370.7 | 20.1 | 145 |
| 3 | O | O | O | + | + | + | D | Y | - | G5P2 | 19.17 | 39+3 | 25h | 326.6 | 66.3 | 74 |
| 4 | A | B | AB | + | + | + | E | N | + | G5P2 | 11.99 | 38+6 | 3d | 361.0 | 30.0 | 105 |
| 5 | A | A | A | + | + | + | E、c | Y | + | G3P2 | 18.25 | 37+1 | 24h | 469.3 | 30.5 | 83 |
| 6 | B | A | AB | + | + | + | E | Y | + | G3P2 | 25.30 | 40+3 | 32h | 471.1 | 75.6 | 76 |
| 7 | A | B | A | + | + | + | E | N1 | + | G3P2 | 3.95 | 37+6 | 3d | 407.0 | 18.1 | 208 |
| 8 | O | O | O | + | + | + | D | Y | - | G3P3 | 3.63 | 40+6 | 5d | 365.7 | 28.7 | 120 |
| 9 | A | AB | AB | + | + | + | E | N | + | G2P2 | 1.12 | 40+2 | 8d | 228.9 | 21.4 | 122 |
| 10 | O | AB | B | + | + | + | D | Y | + | G4P3 | 8.07 | 39+0 | 20h | 282.1 | 33.1 | 137 |
| 11 | A | B | B | + | + | + | E | Y | + | G4P2 | 22.97 | 38+4 | 11h | 257.4 | 28.1 | 97 |
| 12 | O | O | O | + | + | + | E | N1 | + | G2P2 | 15.62 | 39+4 | 21h | 347.9 | 16.3 | 121 |
| 13 | O | O | O | + | + | + | C | N | + | G2P2 | 12.20 | 39+2 | 3d | 275.4 | 10.0 | 106 |
| 14 | A | B | AB | + | + | + | D | Y | - | G2P2 | 18.53 | 40+0 | 10h | 249.9 | 14.6 | 113 |
| 15 | O | AB | B | + | + | + | E | Y | + | G2P2 | 8.67 | 39+2 | 10h | 447.4 | 21.3 | 93 |
| 16 | A | B | B | + | + | + | c | N | + | G2P2 | 2.88 | 37+6 | 6d | 312.5 | 32.4 | 160 |
| 17 | A | A | A | + | + | + | D | Y | - | G2P2 | 18.53 | 39+4 | 14h | 292.4 | 26.2 | 105 |
| 18 | B | AB | B | + | + | + | E | N | + | G3P2 | 4.50 | 39+0 | 3d | 288.6 | 21.5 | 138 |

1Newborn received intensive phototherapy after meeting threshold of BET due to refusal by parents. F: Father; M: Mother; N: Newborn; BET: Blood exchange transfusion; T-bil: Total bilirubin; D-bil: Direct bilirubin.